EUCTR2012-001948-21-ES进行中（未招募）不适用
Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study. - GreKo
Grupo Español de Tumores Huérfanos e Infrecuentes0 个研究点开始时间: 2012年5月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Patients obtained their written informed consent.
- •- Women >= 18 years old.
- •- ECOG <= 1.
- •- Histologically confirmed carcinoma of granulosa cell in ovary.
- •- Availability of sufficient biopsy material to confirm the diagnosis by a centralized pathologist and determination of the FOXL2 402C mutation - G (C134W).
- •- Metastatic or unresectable disease.
- •- Imaging measurable disease.
- •- Life expectancy >= 12 weeks.
- •- Patients with adequate hepatic function, defined by:
- •* Serum values of AST and ALT <= 3 x UNL (except in the presence of metastases then allowed values <= 5 x UNL)
- •* Total bilirubin <= 1.5 x UNL
- •- Patients with adequate bone marrow function, defined by:
- •* Absolute neutrophil count >= 1.5 x 10*9 / L
- •* Platelets >= 100 x 10*9 / L
- •* Hb > 9 g / dL
- •- Patients with adequate renal function: serum creatinine <= 1.5 x UNL.
- •- Absence of any impediment to comply with the study protocol.
- •- Women of childbearing potential, sexually active, not under hysterectomy or bilateral adnexectomy, should follow the following guidelines on contraception:
- •- Negative serum or urine pregnancy test within 72 hours before the start of treatment.
- •- Use of a medically accepted contraceptive method during: the 2 months prior to study treatment, during the study and 3 months after the last dose of study treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •- Patients with another primary tumor 2 years before starting the study drug, with the exception of cervical carcinoma in situ or adequately treated or removed completely or basalioma or superficial bladder carcinoma.
- •- Patients received radical radiotherapy <= 4 weeks before starting the study treatment or who have not recovered from the toxicities of radiotherapy. Palliative radiotherapy of painful bone lesions is allowed up to 14 days before the start of study treatment.
- •- Patients with heart failure or clinically significant heart disease, including any of the following:
- •* History or presence of uncontrolled severe ventricular arrhythmia.
- •* Clinically significant bradycardia at rest.
- •* LVEF <45% assessed by 2-D echocardiogram (ECHO) or MUGA. However, these tests are not mandatory per protocol.
- •- Any of the following diseases within 6 months prior to the start of study drug: Myocardial infarction (MI), severe or unstable angina, coronary revascularization, congestive heart failure (CHF), stroke (CVA), transient ischemic attack (TIA).
- •- Patients with gastrointestinal function failure or gastric disease that significantly alter the ketoconazole absorption, for example, severe ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption, extensive resection (> 1m) of the small intestine or inability to swallow oral medication.
- •- Diagnosis of infection with human immunodeficiency virus (HIV).
- •- Pregnant women or nursing.
- •- Women of childbearing potential not using effective contraceptive method.
- •- Patients who are unwilling or unable to comply with the protocol.
研究者
相似试验
终止
2 期
Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of OvaryGranulosa Cell Tumour of the OvaryNCT01584297Grupo Español de Tumores Huérfanos e Infrecuentes6
进行中（未招募）
不适用
A study with ketoconazole and octreotide combination therapy for treatment of Cushing’s disease.Cushing's disease (which is caused by an ACTH producing pituitary adenoma)MedDRA version: 14.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 10014698 - Endocrine disordersEUCTR2011-003264-77-NLErasmus MC
已完成
2 期
A prospective trial with ketoconazole and octreotide combination therapy for treatment of Cushing*s disease.Cushing's diseasepituitary ACTH hypersecretion10021112NL-OMON36055Erasmus MC, Universitair Medisch Centrum Rotterdam10
已完成
1 期
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199Non-Hodgkin's LymphomaNCT01969669AbbVie12
已完成
2 期
A phase 2, randomized, vehicle and ketoconazole-controlled, evaluator-blinded, study to explore the efficacy, pharmacodynamics and safety of omiganan 1.75% topical gel BID in patients with mild to moderate facial seborrheic dermatitis.seborrheic dermatitisNL-OMON48780Maruho Co., Ltd.36